These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Gancyclovir prophylaxis in high risk patients. Campino A Transplant Proc; 2005 Dec; 37(10):4311-2. PubMed ID: 16387106 [TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience. Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934 [TBL] [Abstract][Full Text] [Related]
9. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354 [TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L; Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546 [TBL] [Abstract][Full Text] [Related]
11. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085 [TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus infection in living donor liver transplant recipients significantly impacts the early post-transplant outcome: A single center experience. Yadav SK; Saigal S; Choudhary NS; Saha S; Sah JK; Saraf N; Kumar N; Goja S; Rastogi A; Bhangui P; Soin AS Transpl Infect Dis; 2018 Aug; 20(4):e12905. PubMed ID: 29668120 [TBL] [Abstract][Full Text] [Related]
13. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease]. Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888 [TBL] [Abstract][Full Text] [Related]
14. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors. Shah T; Lai WK; Mutimer D Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091 [TBL] [Abstract][Full Text] [Related]
16. Deferred versus prophylactic therapy with gancyclovir for cytomegalovirus in allograft liver transplantation. Lianghui G; Shusen Z; Tingbo L; Yan S; Weilling W; Anwei L Transplant Proc; 2004 Jun; 36(5):1502-5. PubMed ID: 15251371 [TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus infection in kidney transplant recipients: Evolution of approach through three eras. Boucher A; Lord H; Collette S; Morin M; Dandavino R Transplant Proc; 2006 Dec; 38(10):3506-8. PubMed ID: 17175316 [TBL] [Abstract][Full Text] [Related]